American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 29, Issue 6 , Pages 403-413 , November 2008

Safety of intranasal corticosteroids in acute rhinosinusitis

  • Pascal Demoly, MD

      Affiliations

    • Corresponding Author InformationClinical Department of Allergology, Maladies Respiratoires, INSERM U657, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France.

Received 24 September 2007

References 

  1. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol. 2004;113(Suppl 193):3–5
  2. Pleis JR, Coles R. Summary health statistics for U.S. adults: National Health Interview Survey, 1998. National Center for Health Statistics. Vital Health Stat. 2002;10:1–113
  3. Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol Head Neck Surg. 1997;116(6 Pt 2):S1–S20
  4. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. National Health Center for Health Statistics. Vital Health Stat 13. 2006;159:1–66
  5. Slavin RG, Spector SL, Bernstein IL. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. 2005;116:S13–S47
  6. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004;114:S155–S212
  7. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116:1289–1295
  8. Fokkens W, Lund V, Mullol J on behalf of the European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology. 2007;1-136(Suppl 20):
  9. Pitkaranta A, Arruda E, Malmberg H, et al. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microbiol. 1997;35:1791–1793
  10. Pitkaranta A, Starck M, Savolainen S, et al. Rhinovirus RNA in the maxillary sinus epithelium of adult patients with acute sinusitis. Clin Infect Dis. 2001;33:909–911
  11. MacNaughton MR. Occurrence and frequency of coronavirus infections in humans as determined by enzyme-linked immunosorbent assay. Infect Immun. 1982;38:419–423
  12. Gwaltney JM, Sydnor A, Sande MA. Etiology and antimicrobial treatment of acute sinusitis. Ann Otol Rhinol Laryngol. 1981;90:68–71
  13. Wald ER, Milmoe GJ, Bowen A. Acute maxillary sinusitis in children. N Engl J Med. 1981;304:749–754
  14. Gwaltney JM. The common cold. In:  Mandell GL,  Douglas RG,  Bennett JE editor. Principles and practice of infectious diseases. 3rd ed.. New York (NY): Churchill Livingstone; 1990;p. 489–493
  15. Lau J, Zucker D, Engels EA, et al. Diagnosis and treatment of acute bacterial rhinosinusitis. Evidence Report/Technology Assessment No. 9 (Contract 290-97-0019 to the New England Medical Center). Rockville (Md): Agency for Health Care Policy and Research; 1999;Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.13219 Accessed April 17, 2007
  16. Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23:1209–1223
  17. van Cauwenberge P, Van Hoecke H, Vandenbulcke L, et al. Glucocorticosteroids in allergic inflammation: clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media. Immunol Allergy Clin North Am. 2005;25:489–509
  18. Berg O, Carenfelt C, Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis. 1988;20:511–516
  19. Slavin RG. Sinusitis in adults and its relation to allergic rhinitis, asthma, and nasal polyps. J Allergy Clin Immunol. 1988;82:950–956
  20. Spector SL, Bernstein IL, Li JT, et al. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol. 1998;102(6 Pt 2):S107–S144
  21. Mygind N, Nielsen LP, Hoffmann HJ, et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108:S16–S25
  22. Hutchison KA, Scherrer LC, Czar MJ, et al. Regulation of glucocorticoid receptor function through assembly of a receptor-heat shock protein complex. Ann NY Acad Sci. 1993;684:35–48
  23. Wissink S, van de Stolpe A, Caldenhoven E, et al. NF-kappa B/Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells. Immunobiology. 1997;198:50–64
  24. LeVan TD, Behr FD, Adkins KK, et al. Glucocorticoid receptor signaling in a bronchial epithelial cell line. Am J Physiol. 1997;272:L838–L843
  25. Dolor RJ, Witsell DL, Hellkamp AS, et al. for the Ceftin and Flonase for Sinusitis (CAFFS) Investigators Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis: The CAFFS trial: a randomized controlled trial. JAMA. 2001;286:3097–3105
  26. Kim KT, Rabinovitch N, Uryniak T, et al. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004;93:61–67
  27. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg. 2004;130:187–191
  28. Opatowsky I, Feldman RM, Gross R. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102:177–179
  29. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–1063
  30. Pauwels RA, Pedersen S, Busse WW, et al. on behalf of the START Investigators' Group Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–1076
  31. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–1909
  32. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56:272–278
  33. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345:941–947
  34. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000;355:1399–1403
  35. Hubbard RB, Smith CJP, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166:1563–1566
  36. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8–14
  37. Garbe E, LeLorier J, Biovin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722–727
  38. Haynes RC. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In:  Rall TW,  Nies AS,  Taylor P editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed.. New York (NY): Pergamon Press; 1990;p. 1431–1462
  39. Pauwels RA, Lofdahl CG, Laitinen LA, et al. for the European Society Respiratory Study on Chronic Obstructive Pulmonary Disease Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340:1948–1953
  40. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23:11–33
  41. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare?. J Allergy Clin Immunol. 1999;104:S144–S149
  42. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97:169–176
  43. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol. 2000;106:S179–S190
  44. Daley-Yates PT, Richards HR. Pharmacokinetic and pharmacodynamic relationships for intranasal corticosteroids (INCS). J Allergy Clin Immunol. 2001;107:S313
  45. Richards DH, Daley-Yates PT. Choice of inhaled and intranasal steroids when used in combination for asthma and rhinitis in children. Allergy. 2000;55:61;(abstr 185) (suppl)
  46. Pakes GE, Brogden RN, Heel RC, et al. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs. 1980;19:397–411
  47. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999;104(Suppl):S150–S158
  48. Daley-Yates PT, McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drops (FP-Drops) and aqueous nasal spray formulations (FPANS). Allergy. 1998;53:412;(abstr)
  49. Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004;60:265–268
  50. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22
  51. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:e23
  52. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25:699–717
  53. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamines, depot and intranasal glucocorticosteroids. Acta Paediatr. 1993;82:635–640
  54. Wolthers OD. Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids. Eur Respir J. 1996;9:821–827
  55. Kaliner M. Rhinosinusitis—the role of the allergist in diagnosis and treatment. Allergy Clin Immunol Int. 1998;10:141–148
  56. McNally PA, White MV, Kaliner MA. Sinusitis in an allergists' office: analysis of 200 consecutive cases. Allergy Asthma Proc. 1997;18:169–175
  57. Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics. 1991;87:311–316
  58. Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy. 1989;44:116–122
  59. Kogutt MS, Swischuk LE. Diagnosis of sinusitis in infants and children. Pediatrics. 1973;52:121–124
  60. Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol. 1998;101(2 pt 2):S357–S360
  61. Giger R, Pasche P, Cheseaux C, et al. Comparison of once- versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2003;260:135–140
  62. Nayak AS, Settipane GA, Pedinoff A, et al. and the Nasonex Sinusitis Group Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89:271–278
  63. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy. 1997;52:620–626
  64. Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy. 1988;18:253–259
  65. Brannan MD, Herron JM, Reidenberg P, et al. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther. 1995;17:637–647
  66. Vargas R, Dockhorn RJ, Findlay SR, et al. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102:191–197
  67. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92:594–599
  68. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol. 1998;101(2 Pt 1):157–162
  69. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;1330–1339
  70. Allen DB, Meltzer EO, Lemanske RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23:407–413
  71. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol. 1999;104:948–952
  72. Munk ZM, LaForce C, Furst JA, et al. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;77:277–281
  73. Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98:724–731
  74. Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol. 1993;92:812–823
  75. Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol. 1997;78:598–601
  76. Yilmaz G, Varan B, Yilmaz T, et al. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Eur Arch Otorhinolaryngol. 2000;257:256–259
  77. Meltzer EO, Charous BL, Busse WW, et al. and the Nasonex Sinusitis Group Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. J Allergy Clin Immunol. 2000;106:630–637
  78. Lund VJ, Black JH, Szabo LZ. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology. 2004;42:57–62

PII: S0196-0709(07)00216-5

doi: 10.1016/j.amjoto.2007.11.004

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 29, Issue 6 , Pages 403-413 , November 2008

Article Tools

* Image Usage & Resolution